Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Blood blood.2024025738.

https://doi.org/10.1182/blood.2024025738

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial

Blood (2024) 144 (Supplement 1): 1053.

https://doi.org/10.1182/blood-2024-208486

Published: 2024

Journal Articles

Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec

Laurent Frenzel, Kaan Kavakli, Andrew D. Leavitt, Ali Bülent Antmen, Davide Matino, Margareth Ozelo, Hazza Alzahrani, Barbara A. Konkle, Maria de los Angeles Resa, Annie F. Fang, Jasmine Healy, Delphine Agathon, Francesca Biondo, Frank Plonski

Blood (2024) 144 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2024-193368

Published: 2024

Journal Articles

Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety

Ben Samelson-Jones, Laurent Frenzel, Kaan Kavakli, Adam Cuker, Jerome M. Teitel, Pengling Sun, Lisa J Wilcox, Francesca Biondo, Benjamin Hutter, John McKay, Delphine Agathon, Frank Plonski

Blood (2024) 144 (Supplement 1): 3577.

https://doi.org/10.1182/blood-2024-193453

Published: 2024

Journal Articles

Infection Risk and Efficacy of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: A Real-World Propensity Score-Matched Study

Jeremie Zerbit, Guillemette Fouquet, Marion Detroit, Sylvain Choquet, Laurent Garderet, Olivier Hermine, Clarisse Cazelles, Laurent Frenzel, Mohamad Mohty, Zoe Van De Wyngaert, Harel Stephanie, Karim Belhadj Merzoug, Sabine Brechignac, Didier Bouscary, Cyrielle Rodier, Romain Winer, Mathis Collier, Marguerite Vignon

Blood (2024) 144 (Supplement 1): 5141.

https://doi.org/10.1182/blood-2024-199978

Published: 2024

Journal Articles

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2024-198119

Published: 2024

Journal Articles

Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

Blood (2024) 144 (Supplement 1): 4343.

https://doi.org/10.1182/blood-2024-193883

Published: 2024

Journal Articles

Reducing Infection Risks of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: In-Hospital Vs. Hospital-at-Home Treatment

Blood (2024) 144 (Supplement 1): 2286.

https://doi.org/10.1182/blood-2024-204695

Published: 2024

Journal Articles

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Jill Corre, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Thierry Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chrétien, Sophie Godet, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Jean Pierre Marolleau, Pascal Godmer, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Amine Kasmi, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Cyrille Hulin, Xavier Leleu

Blood (2024) 144 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2024-210345

Published: 2024

Journal Articles

RAS/RAF landscape in monoclonal plasma cell conditions

Blood (2024) 144 (2): 201–205.

https://doi.org/10.1182/blood.2023022295

Published: 2024

Includes: Supplemental data

Journal Articles

Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis

Laurent Frenzel, Kaan Kavakli, Robert Klamroth, Shyh-Shin Chiou, Amy D. Shapiro, Pengling Sun, Joanne Fuiman, John McKay, Annie F. Fang, Francesca Biondo, Frank Plonski, Jeremy Rupon

Blood (2023) 142 (Supplement 1): 2257.

https://doi.org/10.1182/blood-2023-181223

Published: 2023

Journal Articles

Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated before the Anti-CD38 Antibodies Era in France, the Emmy Cohort 2017 to 2020

Blood (2023) 142 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2023-173845

Published: 2023

Journal Articles

Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies

Blood (2023) 142 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2023-175004

Published: 2023

Journal Articles

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

Mael Heiblig, Clement Gourguechon, Philippe Guilpain, Cristina Bulai Livideanu, Stéphane Barete, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Gandhi Laurent Damaj, Thomas Ballul, Céline Greco, Laura Polivka, Laurent Frenzel, Cecile Meni, Hassiba Bouktit, Caroline Gaudy-Marqueste, Marie Gousseff, Edwige Le Mouel, Antoine Neel, Dana Ranta, Roland Jaussaud, Thierry Jo Molina, Julie Bruneau, Ludovic Lhermitte, Marie Temple, Olivier Kosmider, Rose-Marie Javier, Fabien Pelletier, Florence Castelain, Frédérique Retornaz, Quentin Cabrera, Patricia Zunic, Marie-Pierre Gourin, Ewa Wierzbicka-Hainaut, Jean-Francois Viallard, Christian Lavigne, Cyrille Hoarau, Isabelle Durieu, Sophie Dimicoli-Salazar, Jose-Miguel Torregrosa-Diaz, Angele Soria, Michel Arock, Christine Bodemer, Olivier Lortholary, Olivier Hermine, Julien Rossignol

Blood (2023) 142 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2023-185890

Published: 2023

Journal Articles

Health Care Resource Use, Comorbidities, and Costs of Hemophilia B Patients in France: A Nationwide Claims Database Analysis

Laurent Frenzel, Véronique Cahoreau, Nicolas Giraud, Stephanie Delienne, Francis Fagnani, Stéphane Bouée, Juliette Cottin, Isabelle Bureau, Jeremie Rudant, Anais Reynaud, Amelie Coumert, Herve Lilliu, Aurelien Lebreton

Blood (2023) 142 (Supplement 1): 3982.

https://doi.org/10.1182/blood-2023-173445

Published: 2023

Journal Articles

Health Care Resource Use, Comorbidities, and Costs of Hemophilia A Patients in France: A Nationwide Claims Database Analysis

Aurelien Lebreton, Véronique Cahoreau, Nicolas Giraud, Stephanie Delienne, Francis Fagnani, Stéphane Bouée, Juliette Cottin, Isabelle Bureau, Jeremie Rudant, Anais Reynaud, Amelie Coumert, Herve Lilliu, Laurent Frenzel

Blood (2023) 142 (Supplement 1): 1237.

https://doi.org/10.1182/blood-2023-173257

Published: 2023

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Blood (2022) 140 (Supplement 1): 10133–10136.

https://doi.org/10.1182/blood-2022-163555

Published: 2022

Journal Articles

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Blood (2022) 140 (Supplement 1): 4379–4381.

https://doi.org/10.1182/blood-2022-158484

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 10150–10153.

https://doi.org/10.1182/blood-2022-163335

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 7297–7300.

https://doi.org/10.1182/blood-2022-163494

Published: 2022

NARROW

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial

Results from the Hemophilia Α Cohort of the Non-Investigational Lead-in Study: Prospective Collection of Bleeding Rate in Participants with Hemophilia Α Prior to Phase 3 Study (AFFINE) of Giroctocogene Fitelparvovec

Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety

Infection Risk and Efficacy of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: A Real-World Propensity Score-Matched Study

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Inflammatory Waldenström Macroglobulinemia Is Associated with Clonal Hematopoiesis: A Multicentric Cohort

Reducing Infection Risks of Anti-BCMA Bispecific Antibodies in Multiple Myeloma: In-Hospital Vs. Hospital-at-Home Treatment

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

RAS/RAF landscape in monoclonal plasma cell conditions

Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis

Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated before the Anti-CD38 Antibodies Era in France, the Emmy Cohort 2017 to 2020

Cumulative Incidence and Characteristics of Infections Requiring Treatment, Delay in Treatment Administration or Hospitalisation in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti BCMA or Anti GPRC5D Bispecific Antibodies

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

Health Care Resource Use, Comorbidities, and Costs of Hemophilia B Patients in France: A Nationwide Claims Database Analysis

Health Care Resource Use, Comorbidities, and Costs of Hemophilia A Patients in France: A Nationwide Claims Database Analysis

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only